April 13, 2018 / 8:31 PM / 3 months ago

BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies

April 13 (Reuters) - Bristol-Myers Squibb Co:

* BRISTOL-MYERS SQUIBB AND ILLUMINA ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE COMPANION DIAGNOSTICS FOR BRISTOL-MYERS SQUIBB’S ONCOLOGY IMMUNOTHERAPIES

* EXPANDS ILLUMINA’S ONCOLOGY OFFERINGS FOR NEXTSEQ 550DX

* COS PLAN TO DEVELOP A DIAGNOSTIC VERSION OF ILLUMINA TRUSIGHT ONCOLOGY 500 ASSAY TO MEASURE POTENTIALLY PREDICTIVE GENOMIC BIOMARKERS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below